News
Novo Nordisk's Wegovy Showdown: Navigating Market Pressures and Potential Layoffs
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job cuts. Despite lucrative past sales, Novo warns of slower growth due to rival generics and compounding pharmacies,
Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
1dOpinion
The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback